Trials including patients experiencing second or higher relapse of ovarian cancer

Trial name	Intervention	Proportion of patients with more than one line of previous chemotherapy	Platinum sensitivity (interval since last chemotherapy)
Platinum-sensitive			
Bafaloukos et al.[29]	PLDH plus carboplatin	4/93 (4%) (≥2 lines of prior chemotherapy)	6–12 months: 22/93 (23%) 12.1–24 months: 38/93 (41%) >24 months: 29/93 (31%)
	Paclitaxel plus carboplatin	4/96 (4%) (≥2 lines of prior chemotherapy)	6–12 months: 32/96 (33%) 12.1–24 months: 32/96 (33%) >24 months: 23/96 (24%)
CALYPSO *(Pujade-Lauraine* et al.[31]*)*	PLDH plus carboplatin	58/466 (12.4%) (2 lines of prior chemotherapy)	6–12 months: 161/466 (35.0%) >12 months: 305/466 (65.0%)
	Paclitaxel plus carboplatin	88/466 (17.3%) (2 lines of prior chemotherapy)	6–12 months: 183/466 (36.1%) >12 months: 324/466 (63.9%)
ICON4/AGO-OVAR 2.2 (Parmar et al.[60]	Paclitaxel plus platinum	37/392 (9.4%)	6–12 months: 92/392 (35.0%)

		(5.6% with 2 lines of prior chemotherapy and 3.8% with ≥2 lines)	>12 months: 300/392 (65.0%)
	Platinum monotherapy	30/410 (7.3%) (5.9% with 2 lines of prior chemotherapy and 1.5% with ≥2 lines)	6–12 months: 111/410 (27.1%)
			>12 months: 299/410 (72.9%)
Gonzalez-Martin et al.[47]	Paclitaxel plus carboplatin	7/41 (18.4%) (2 lines of prior chemotherapy)	6–12 months: 17/41 (45%)
			>12 months: 21/41 (55%)
	Carboplatin alone	5/40 (12.5%) (2 lines of prior chemotherapy)	6–12 months: 16/40 (40%)
			>12 months: 24/40 (60%)
Platinum-resistant/refractory			
Sehouli et al.[23]	Weekly topotecan	28/97 (29%)	All patients platinum-resistant
	Conventional topotecan	31/97 (32%)	All patients platinum-resistant
CARTAXHY *(Lortholary* et al.[61]*)*	Weekly paclitaxel plus carboplatin	15/51 (29%) (all 2 lines of prior chemotherapy)	All patients platinum-resistant
	Weekly paclitaxel	15/57 (26%)	All patients platinum-resistant

		(19% with 2 lines of prior chemotherapy and 7% with >2 lines of prior chemotherapy)	
Mixed PFI			
Piccart et al.[62]	Paclitaxel	11/41 (27%) (2 lines of prior chemotherapy)	<6 months: 31/41 (76%)
			6–12 months: 10/41 (24%)
	Oxaliplatin	16/45 (36%) (2 lines of prior chemotherapy)	<6 months: 32/45 (71%)
			6–12 months: 13/45 (29%)

Trials limited to patients experiencing first relapse of ovarian cancer

Trial name	Intervention	Proportion of patients with more than one line of previous chemotherapy	Platinum sensitivity (interval since last chemotherapy)
Platinum-sensitive			
Alberts et al.[28]	PLDH plus carboplatin	0/31 (0%)	6–12 months: 13/31 (43%) 12–24 months: 18/31 (57%)
	Carboplatin alone	0/30 (0%)	6–12 months: 13/30 (43%)

			12–24 months: 17/30 (57%)
OVA-301 (Monk et al. *[2010]*[30]*)* ***Trial includes a patients with refractory ovarian cancer but results for subgroup of platinum-sensitive patients reported separately (licensed population)***	Trabectedin plus PLDH	0/337 (0%)	<6 months: 115/333 (35%) 6–12 months: 123/333 (37%) >12 months: 95/333 (28%)
	PLDH alone	0/335 (0%)	<6 months: 117/330 (35%) 6–12 months: 91/330 (28%) >12 months: 122/330 (37%)
Pfisterer et al.[49]	Gemcitabine plus carboplatin	0/178 (0%)	6–12 months: 71/178 (39.9%)
			>12 months: 106/178 (59.6%)
	Carboplatin alone	0/178 (0%)	6–12 months: 71/178 (39.9%)
			>12 months: 107/178 (60.1%)
Mixed PFI			
Gordon et al. *(2001)*[48]	PLDH	0/239 (0%)	<6 months: 130/239 (54.4%) ≥6 months: 109/239 (45.6%)
	Topotecan	0/235 (0%)	<6 months: 130/239 (54.4%) ≥6 months: 109/239 (45.6%)
Trial 30-57[13]	PLDH	0/108 (0%)	Not reported

	Paclitaxel	0/108 (0%)	<6 months: 67/108 (62%) ≥6 months: 41/108 (38%)
ten Bokkel Huinink et al. *(1997)*[21]	Topotecan	0/117 (0%)	<6 months: 52/112 (46.4%) ≥6 months: 60/112 (53.6%)
	Paclitaxel	0/118 (0%)	<6 months: 55/114 (48.4%) ≥6 months: 59/114 (51.8%)
Gore et al.[24]	Oral topotecan	0/135 (0%)	Platinum sensitive: 58 (43%)
			Platinum resistant: 37 (27%)
			Platinum refractory: 40 (30%)
	Intravenous topotecan	0/131 (0%)	Platinum sensitive: 56 (43%)
			Platinum resistant: 36 (27%)
			Platinum refractory: 39 (30%)
Omura et al.[66]	Paclitaxel 250 mg/m^2	0/166 (0%)	<6 months: 132/166 (79%) >6 months: 34/166 (21%)
	Paclitaxel 175 mg/m^2	0/164 (0%)	<6 months: 125/164 (76%) >6 months: 39/164 (24%)
Rosenberg et al.[59]	Weekly paclitaxel	0/105 (0%)	<6 months: 57/105 (54%)

			>6 months: 48/105 (46%)
	Three-weekly paclitaxel	0/103 (0%)	<6 months: 51/103 (50%) >6 months: 52/103 (50%)